Literature DB >> 31646442

Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance.

Justin Mower1, Trevor Cohen2, Devika Subramanian3.   

Abstract

INTRODUCTION: As a result of the well documented limitations of data collected by spontaneous reporting systems (SRS), such as bias and under-reporting, a number of authors have evaluated the utility of other data sources for the purpose of pharmacovigilance, including the biomedical literature. Previous work has demonstrated the utility of literature-derived distributed representations (concept embeddings) with machine learning for the purpose of drug side-effect prediction. In terms of data sources, these methods are complementary, observing drug safety from two different perspectives (knowledge extracted from the literature and statistics from SRS data). However, the combined utility of these pharmacovigilance methods has yet to be evaluated.
OBJECTIVE: This research investigates the utility of directly or indirectly combining an observational signal from SRS with literature-derived distributed representations into a single feature vector or in an ensemble approach for downstream machine learning (logistic regression).
METHODS: Leveraging a recently developed representation scheme, concept embeddings were generated from relational connections extracted from the literature and composed to represent drug and associated adverse reactions, as defined by two reference standards of positive (likely causal) and negative (no causal evidence) pairs. Embeddings were presented with and without common measures of observational signal from SRS sources to logistic regressors, and performance was evaluated with the receiver operating characteristic (ROC) area under the curve (AUC) metric.
RESULTS: ROC AUC performance with these composite models improves up to ≈ 20% over SRS-based disproportionality metrics alone and exceeds the best prior results reported in the literature when models leverage both sources of information.
CONCLUSIONS: Results from this study support the hypothesis that knowledge extracted from the literature can enhance the performance of SRS-based methods (and vice versa). Across reference sets, using literature and SRS information together performed better than using either source alone, providing strong support for the complementary nature of these approaches to post-marketing drug surveillance.

Entities:  

Mesh:

Year:  2020        PMID: 31646442      PMCID: PMC7243821          DOI: 10.1007/s40264-019-00872-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  37 in total

1.  The interaction of domain knowledge and linguistic structure in natural language processing: interpreting hypernymic propositions in biomedical text.

Authors:  Thomas C Rindflesch; Marcelo Fiszman
Journal:  J Biomed Inform       Date:  2003-12       Impact factor: 6.317

Review 2.  The reporting odds ratio and its advantages over the proportional reporting ratio.

Authors:  Kenneth J Rothman; Stephan Lanes; Susan T Sacks
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

Review 3.  Data mining for signals in spontaneous reporting databases: proceed with caution.

Authors:  Wendy P Stephenson; Manfred Hauben
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

4.  Using the literature-based discovery paradigm to investigate drug mechanisms.

Authors:  Caroline B Ahlers; Dimitar Hristovski; Halil Kilicoglu; Thomas C Rindflesch
Journal:  AMIA Annu Symp Proc       Date:  2007-10-11

5.  Causal or casual? The role of causality assessment in pharmacovigilance.

Authors:  R H Meyboom; Y A Hekster; A C Egberts; F W Gribnau; I R Edwards
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

6.  Embedding of semantic predications.

Authors:  Trevor Cohen; Dominic Widdows
Journal:  J Biomed Inform       Date:  2017-03-08       Impact factor: 6.317

7.  Adverse drug events in the outpatient setting: an 11-year national analysis.

Authors:  Florence T Bourgeois; Michael W Shannon; Clarissa Valim; Kenneth D Mandl
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-09       Impact factor: 2.890

8.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D C Classen; S L Pestotnik; R S Evans; J F Lloyd; J P Burke
Journal:  JAMA       Date:  1997 Jan 22-29       Impact factor: 56.272

9.  Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.

Authors:  Antoine Pariente; Fleur Gregoire; Annie Fourrier-Reglat; Françoise Haramburu; Nicholas Moore
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.

Authors:  Ying Li; Patrick B Ryan; Ying Wei; Carol Friedman
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

View more
  4 in total

1.  Improving Pharmacovigilance Signal Detection from Clinical Notes with Locality Sensitive Neural Concept Embeddings.

Authors:  Justin Mower; Elmer Bernstam; Hua Xu; Sahiti Myneni; Devika Subramanian; Trevor Cohen
Journal:  AMIA Annu Symp Proc       Date:  2022-05-23

2.  The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.

Authors:  Maribel Salas; Jan Petracek; Priyanka Yalamanchili; Omar Aimer; Dinesh Kasthuril; Sameer Dhingra; Toluwalope Junaid; Tina Bostic
Journal:  Pharmaceut Med       Date:  2022-07-29

Review 3.  Machine Learning in Causal Inference: Application in Pharmacovigilance.

Authors:  Yiqing Zhao; Yue Yu; Hanyin Wang; Yikuan Li; Yu Deng; Guoqian Jiang; Yuan Luo
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

Review 4.  Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources.

Authors:  Likeng Liang; Jifa Hu; Gang Sun; Na Hong; Ge Wu; Yuejun He; Yong Li; Tianyong Hao; Li Liu; Mengchun Gong
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.